Today at one side I have been down with fever but one promotion by Quintiles intrigued me " Quintiles: your RA partner"
RA landscape has been the most interesting landscape both in terms of small molecules and bio generics....Abbott had already been a market leader in terms of Humira but Pfizer has big plans for capturing the market share and we need to look at how it’s going to go for its pricing so that it has quick approval from the regulatory bodies in European region...
Now we need to just see if quintiles is going to be trials partner for the major companies who are investing in this segment for both the big daddy’s and bio generics and generic manufacturers in the RA landscape as compared to oncology its comparative easy market entry......What will be the next strategy for Icon, Paraxel, PPD and convance?
RA landscape has been the most interesting landscape both in terms of small molecules and bio generics....Abbott had already been a market leader in terms of Humira but Pfizer has big plans for capturing the market share and we need to look at how it’s going to go for its pricing so that it has quick approval from the regulatory bodies in European region...
Now we need to just see if quintiles is going to be trials partner for the major companies who are investing in this segment for both the big daddy’s and bio generics and generic manufacturers in the RA landscape as compared to oncology its comparative easy market entry......What will be the next strategy for Icon, Paraxel, PPD and convance?
No comments:
Post a Comment